Figure 5 PPIs and adverse events with proven and unproven causality

Slides:

Advertisements

Similar presentations

Ho PM, et al. JAMA 2009;301: Baseline Characteristics of Patients Taking Clopidogrel After Hospital Discharge a Ho PM, et al. JAMA 2009;301:

Advertisements

Wai–Kit Lo, Walter W. Chan Clinical Gastroenterology and Hepatology

Figure 1 Proposed risk stratification for patients with NAFLD

Lucio Lombardo, Monica Foti, Olga Ruggia, Andrea Chiecchio

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Enteroids can model transport physiology

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Activation of clopidogrel via cytochrome P450

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Patients cured of HCV infection

The “dangers” of chronic proton pump inhibitor use

Figure 5 Lipid droplet consumption

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Worldwide incidence of CCA

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Biosimilar development process

Figure 2 Outline of the pathogenesis and overlap

Lucio Lombardo, Monica Foti, Olga Ruggia, Andrea Chiecchio

Figure 3 Algorithm from working group describing

Figure 2 Effect of PPIs on gastric physiology

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Giant lipid droplet formation

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Suggested biopsy-avoiding diagnostic pathway for coeliac disease Figure 1 | Suggested biopsy-avoiding diagnostic pathway for coeliac disease.

Figure 6 Combination therapy for HCC

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 7 Example colonic high-resolution manometry

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Environmental factors contributing to IBD pathogenesis

Figure 1 Tropical sprue and PI-IBS

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Clinical algorithms in the management of NASH and diabetes mellitus Figure 3 | Clinical algorithms in the management of NASH and diabetes mellitus.

Figure 2 13C-octanoic acid gastric emptying breath test

Figure 1 Median coverage and distribution by

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 5 High-resolution manometry studies performed

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 Brain–gut axis Brain–gut axis. Schematic of the brain–gut axis, including inputs from the gut microbiota, the ENS, the immune system and the external.

Figure 3 Optical coherence tomography images of specialized intestinal

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Assessment of colonic transit time with radiopaque markers

Figure 5 Systems biological model of IBS

Figure 4 Local species pools that contribute to the

Figure 1 Endoscopic appearance of fundic gland polyps

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Wai–Kit Lo, Walter W. Chan Clinical Gastroenterology and Hepatology

Fingerprinting of Salmonella enterica subsp

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Lifelong influences on the gut microbiome from

Figure 2 Classifications and appearance of CCAs

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 8 Assessment of colonic tone using a barostat device

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Forest plot of studies examining outcomes between patients taking proton pump inhibitor (PPIs) with clopidogrel and those taking only clopidogrel: (A)

Presentation transcript:

Figure 5 PPIs and adverse events with proven and unproven causality Figure 5 | PPIs and adverse events with proven and unproven causality. The number of complications associated with proton-pump inhibitors (PPIs) is high. This figure shows the adverse events linked to PPI use, with indicators of the evidence supporting causality. Those events with proposed major importance in clinical practice are shown according to the scientific evidence and grading as per Table 1. *Enteric infections with Salmonella enterica subsp. enterica serovar Enteritidis, Salmonella enterica subsp. enterica serovarTyphimurium and Campylobacter jejuni. ‡Association restricted to omeprazole; the FDA recommends avoiding the concomitant use of clopidogrel and omeprazole127. SIBO, small intestinal bacterial overgrowth. Malfertheiner, P. et al. (2017) Proton-pump inhibitors: understanding the complications and risks Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2017.117